<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="425">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05161715</url>
  </required_header>
  <id_info>
    <org_study_id>TA-8995 AD-1</org_study_id>
    <nct_id>NCT05161715</nct_id>
  </id_info>
  <brief_title>Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease</brief_title>
  <official_title>A Phase 2a, Proof-of-Concept, Open-Label Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Obicetrapib in Patients With Early Alzheimer's Disease (Hetero/Homozygote APOE4 Carriers)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewAmsterdam Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewAmsterdam Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a study in men and women with early Alzheimer's disease to evaluate the&#xD;
      pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a proof of concept, Phase 2a study in patients with early Alzheimer's&#xD;
      disease (clinical diagnosis of Alzheimer's disease Stage 3 or 4 based on the National&#xD;
      Institute on Aging Alzheimer's Association Research Framework criteria) to evaluate the&#xD;
      Pharmacodynamic, cognitive effects, Pharmacokinetic, and safety and tolerability of&#xD;
      obicetrapib therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2022</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apolipoproteins in plasma</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apolipoproteins in CSF</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL particle concentration in plasma</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to week 24</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL particle concentration in CSF</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of obicetrapib</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to steady-state blood levels of obicetrapib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF levels of obicetrapib</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change from baseline to steady-state CSF levels of obicetrapib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Early Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>10mg obicetrapib tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obicetrapib</intervention_name>
    <description>10mg obicetrapib</description>
    <arm_group_label>10mg obicetrapib tablets</arm_group_label>
    <other_name>TA-8995</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  men &amp; women 50-75 years&#xD;
&#xD;
          -  post-menopausal or women not of child-bearing potential&#xD;
&#xD;
          -  diagnosis of Alzheimer's disease based on National Institute for Aging:&#xD;
&#xD;
          -  Biomarker classification A+T+N+ or A+T+N-&#xD;
&#xD;
          -  Clinical Stage 3 or 4 with Clinical Dementia Rating score &gt;/= 0.5 &amp; &lt;/= 1; mini-mental&#xD;
             state examination (MMSE) score &gt;/=20&#xD;
&#xD;
          -  Have an APOE genotype of E4/E4 or E3/E4&#xD;
&#xD;
          -  not on or on stabilized AD medication&#xD;
&#xD;
          -  Patient &amp; study partner willing to sign consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other than AD, disorder that may impair cognition&#xD;
&#xD;
          -  Contra-indication for MRI&#xD;
&#xD;
          -  History of neurological, psychiatric or mental conditions;&#xD;
&#xD;
               -  history stroke&#xD;
&#xD;
               -  MI&#xD;
&#xD;
               -  Type 1 diabetes &amp; Type 2 with HbA1c&gt;8%&#xD;
&#xD;
               -  BP &gt; 150/90 mmHg&#xD;
&#xD;
               -  renal or hepatic impaired&#xD;
&#xD;
               -  hyperaldosteronism&#xD;
&#xD;
               -  cancer&#xD;
&#xD;
               -  depression&#xD;
&#xD;
               -  laboratory abnormalities&#xD;
&#xD;
               -  not able to undergo lumbar puncture&#xD;
&#xD;
               -  taking certain medications including lipid altering&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Ditmarsch, MD</last_name>
    <role>Study Director</role>
    <affiliation>NewAmsterdam Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jort Vijverberg, MD</last_name>
    <phone>020-3017170</phone>
    <email>j.vijverberg@brainresearchcenter.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sterre Rutgers, MD</last_name>
    <email>s.rutgers@brainresearchcenter.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brain Research Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E.G.B Vijverberg, MD</last_name>
      <phone>020301770</phone>
      <email>j.vijverberg@brainresearchcenter.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2021</study_first_posted>
  <last_update_submitted>February 9, 2022</last_update_submitted>
  <last_update_submitted_qc>February 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

